| Secondary |
| Colorectal Cancer Metastatic |
13.9% |
| Drug Use For Unknown Indication |
11.3% |
| Pelvic Venous Thrombosis |
10.4% |
| Vena Cava Thrombosis |
8.7% |
| Hepatitis C |
7.8% |
| Acute Lymphocytic Leukaemia |
6.1% |
| Acne |
5.2% |
| Deep Vein Thrombosis |
5.2% |
| Hypertension |
5.2% |
| Staphylococcal Infection |
5.2% |
| Adenocarcinoma |
2.6% |
| Chest Pain |
2.6% |
| Portal Vein Thrombosis |
2.6% |
| Premedication |
2.6% |
| Atrial Fibrillation |
1.7% |
| Candidiasis |
1.7% |
| Colon Cancer Metastatic |
1.7% |
| Helicobacter Infection |
1.7% |
| Hepatic Vein Thrombosis |
1.7% |
| Metastatic Renal Cell Carcinoma |
1.7% |
|
| Anaemia |
15.4% |
| Pruritus |
12.8% |
| Duodenal Ulcer Haemorrhage |
7.7% |
| Urine Output Decreased |
7.7% |
| Candidiasis |
5.1% |
| Eosinophilia |
5.1% |
| Haemorrhage Intracranial |
5.1% |
| Localised Intraabdominal Fluid Collection |
5.1% |
| Oedema Peripheral |
5.1% |
| Thrombocytopenia |
5.1% |
| Angioedema |
2.6% |
| Empyema |
2.6% |
| Hypovolaemic Shock |
2.6% |
| International Normalised Ratio Increased |
2.6% |
| Pulmonary Embolism |
2.6% |
| Subcutaneous Nodule |
2.6% |
| Thrombocythaemia |
2.6% |
| Thrombophlebitis |
2.6% |
| Toxic Epidermal Necrolysis |
2.6% |
| Toxic Skin Eruption |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
35.9% |
| Prophylaxis |
9.2% |
| Diffuse Large B-cell Lymphoma |
5.0% |
| Hypertension |
5.0% |
| Head And Neck Cancer |
4.4% |
| Multiple Myeloma |
4.4% |
| Pulmonary Embolism |
4.4% |
| Product Used For Unknown Indication |
3.2% |
| Colon Cancer |
2.9% |
| Mantle Cell Lymphoma |
2.9% |
| Breast Cancer |
2.7% |
| Phlebitis |
2.7% |
| Anticoagulant Therapy |
2.5% |
| Rheumatoid Arthritis |
2.5% |
| Atrial Fibrillation |
2.3% |
| Pain |
2.3% |
| B-cell Lymphoma |
2.1% |
| Gastric Cancer |
1.9% |
| Antiplatelet Therapy |
1.7% |
| Deep Vein Thrombosis |
1.7% |
|
| Pneumonia |
9.8% |
| Septic Shock |
8.5% |
| Transaminases Increased |
8.5% |
| Renal Failure |
7.3% |
| Thrombocytopenia |
7.3% |
| Weight Decreased |
7.3% |
| Pyrexia |
6.1% |
| Blood Creatinine Increased |
4.9% |
| Lung Disorder |
4.9% |
| Renal Failure Acute |
4.9% |
| Cerebral Infarction |
3.7% |
| International Normalised Ratio Increased |
3.7% |
| Phlebitis |
3.7% |
| Urinary Incontinence |
3.7% |
| Venous Thrombosis |
3.7% |
| Adenocarcinoma |
2.4% |
| Carcinoid Tumour |
2.4% |
| Death |
2.4% |
| Diarrhoea |
2.4% |
| Epistaxis |
2.4% |
|
| Interacting |
| Drug Use For Unknown Indication |
73.7% |
| Arteriopathic Disease |
21.1% |
| Pain In Extremity |
5.3% |
|
| International Normalised Ratio Increased |
66.7% |
| Stress Cardiomyopathy |
33.3% |
|
